Following on from information provided to NICE by the company in November 2020 the appraisal of Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| ID number | 1612 |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 December 2022 | Discontinued. Following on from information provided to NICE by the company in November 2020 the appraisal of Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 December 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 08 May 2019 | In progress. Referred 17 October 2018 |
For further information on our processes and methods, please see our CHTE processes and methods manual